115 related articles for article (PubMed ID: 38109864)
1. Association between Circulating Levels of CXCL9 and CXCL10 and Physical Frailty in Older Adults.
Li J; Hosoyama T; Shigemizu D; Yasuoka M; Kinoshita K; Maeda K; Takemura M; Matsui Y; Arai H; Satake S
Gerontology; 2024; 70(3):279-289. PubMed ID: 38109864
[TBL] [Abstract][Full Text] [Related]
2. [Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis].
Zhong H; Xu LL; Bai MX; Su Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1026-1031. PubMed ID: 34916676
[TBL] [Abstract][Full Text] [Related]
3. CXCL9/CXCL10 angiostasis CXC-chemokines in parallel with the CXCL12 as an angiogenesis CXC-chemokine are variously expressed in pre-eclamptic-women and their neonates.
Darakhshan S; Hassanshahi G; Mofidifar Z; Soltani B; Karimabad MN
Pregnancy Hypertens; 2019 Jul; 17():36-42. PubMed ID: 31487653
[TBL] [Abstract][Full Text] [Related]
4. [Investigate circulating levels of chemokines and evaluate the correlation between these chemokines and liver function indicators in autoimmune hepatitis].
Li YL; Liu N; Zhao DT; Li ZM; Zhang HP; Liu YM; Yan HP; Zhao Y
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):299-303. PubMed ID: 24021794
[TBL] [Abstract][Full Text] [Related]
5. CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis.
Arger NK; Ho ME; Allen IE; Benn BS; Woodruff PG; Koth LL
Respir Med; 2020 Jan; 161():105822. PubMed ID: 31783271
[TBL] [Abstract][Full Text] [Related]
6. Serum IFN-γ-inducible chemokines CXCL9 and CXCL10 are elevated in non-immediate drug hypersensitivity reactions.
Wang F; Cai R; He D; Zhao Y; Ye Y; Zhang X
Asian Pac J Allergy Immunol; 2016 Sep; 34(3):236-241. PubMed ID: 27001652
[TBL] [Abstract][Full Text] [Related]
7. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.
Antonelli A; Ferrari SM; Frascerra S; Galetta F; Franzoni F; Corrado A; Miccoli M; Benvenga S; Paolicchi A; Ferrannini E; Fallahi P
Cytokine; 2011 Aug; 55(2):288-93. PubMed ID: 21601475
[TBL] [Abstract][Full Text] [Related]
8. Interferon-inducible chemokines reflect severity and progression in sarcoidosis.
Su R; Nguyen ML; Agarwal MR; Kirby C; Nguyen CP; Ramstein J; Darnell EP; Gomez AD; Ho M; Woodruff PG; Koth LL
Respir Res; 2013 Nov; 14(1):121. PubMed ID: 24199653
[TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of CCL3, CXCL8, CXCL9, and CXCL10 in rosacea patients and their correlation with disease severity.
Liu T; Li J; Deng Z; Chen M; Sha K; Xiao W; Xie H; Zhao Z
J Dermatol; 2022 May; 49(5):525-533. PubMed ID: 35233832
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata.
Zainodini N; Hassanshahi G; Arababadi MK; Khorramdelazad H; Mirzaei A
Iran J Immunol; 2013 Mar; 10(1):40-6. PubMed ID: 23502337
[TBL] [Abstract][Full Text] [Related]
11. Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients.
Najmaddini H; Hassanshahi G; Ostadebrahimi H; Barkhordari H; Mashayekhi H; Nazari M; Moogooei M; Arababadi YS; Peighambari F; Karimabad MN
Ann Saudi Med; 2014; 34(2):122-7. PubMed ID: 24894780
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.
Rabquer BJ; Tsou PS; Hou Y; Thirunavukkarasu E; Haines GK; Impens AJ; Phillips K; Kahaleh B; Seibold JR; Koch AE
Arthritis Res Ther; 2011 Feb; 13(1):R18. PubMed ID: 21303517
[TBL] [Abstract][Full Text] [Related]
13. CXCL9 and CXCL10 display an age-dependent profile in Chagas patients: a cohort study of aging in Bambui, Brazil.
de Araújo FF; Lima Torres KC; Viana Peixoto S; Pinho Ribeiro AL; Vaz Melo Mambrini J; Bortolo Rezende V; Lima Silva ML; Loyola Filho AI; Teixeira-Carvalho A; Lima-Costa MF; Martins-Filho OA
Infect Dis Poverty; 2020 May; 9(1):51. PubMed ID: 32393333
[TBL] [Abstract][Full Text] [Related]
14. The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.
Yin X; Wang Z; Wu T; Ma M; Zhang Z; Chu Z; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
J Transl Med; 2019 Dec; 17(1):417. PubMed ID: 31836011
[TBL] [Abstract][Full Text] [Related]
15. Cumulative exposure to gamma interferon-dependent chemokines CXCL9 and CXCL10 correlates with worse outcome after lung transplant.
Neujahr DC; Perez SD; Mohammed A; Ulukpo O; Lawrence EC; Fernandez F; Pickens A; Force SD; Song M; Larsen CP; Kirk AD
Am J Transplant; 2012 Feb; 12(2):438-46. PubMed ID: 22151926
[TBL] [Abstract][Full Text] [Related]
16. Circulating CXCL9 and CXCL10 as markers of activity of Graves' orbitopathy during treatment with corticosteroids and teleradiotherapy.
Mysliwiec J; Palyga I; Kosciuszko M; Kowalska A; Gorska M
Horm Metab Res; 2012 Dec; 44(13):957-61. PubMed ID: 22752955
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.
Edvardsen K; Bjånesøy T; Hellesen A; Breivik L; Bakke M; Husebye ES; Bratland E
J Interferon Cytokine Res; 2015 Oct; 35(10):759-70. PubMed ID: 25978633
[TBL] [Abstract][Full Text] [Related]
18. Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10.
Nogueira LG; Santos RH; Ianni BM; Fiorelli AI; Mairena EC; Benvenuti LA; Frade A; Donadi E; Dias F; Saba B; Wang HT; Fragata A; Sampaio M; Hirata MH; Buck P; Mady C; Bocchi EA; Stolf NA; Kalil J; Cunha-Neto E
PLoS Negl Trop Dis; 2012; 6(10):e1867. PubMed ID: 23150742
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection.
Karason K; Jernås M; Hägg DA; Svensson PA
BMC Cardiovasc Disord; 2006 Jun; 6():29. PubMed ID: 16780603
[TBL] [Abstract][Full Text] [Related]
20. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases.
Tacke F; Zimmermann HW; Berres ML; Trautwein C; Wasmuth HE
Liver Int; 2011 Jul; 31(6):840-9. PubMed ID: 21645215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
